Issue 15, 2022

β-Galactosidase-dependent metabolic glycoengineering of tumor cells for imaging and immunotherapy

Abstract

A β-Gal-dependent metabolic glycoengineering strategy was developed for tumor cell-selective surface glycan imaging with high efficacy. Combined with an antibody-recruiting strategy, targeted immunotherapy was achieved successfully based on this strategy.

Graphical abstract: β-Galactosidase-dependent metabolic glycoengineering of tumor cells for imaging and immunotherapy

Supplementary files

Article information

Article type
Communication
Submitted
23 Nov 2021
Accepted
20 Jan 2022
First published
21 Jan 2022

Chem. Commun., 2022,58, 2568-2571

β-Galactosidase-dependent metabolic glycoengineering of tumor cells for imaging and immunotherapy

Y. Li, L. Gong, H. Hong, H. Lin, D. Li, J. Shi, Z. Zhou and Z. Wu, Chem. Commun., 2022, 58, 2568 DOI: 10.1039/D1CC06575K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements